| Range: | 2.68-8.38 | Vol Avg: | 57598 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | 0 | Cap: | 0.05B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jun 14 2023 | Empoloyees: | 13 | ||
| CUSIP: | 38942Q202 | CIK: | 0001534133 | ISIN: | US38942Q2021 | Country: | US |
| CEO: | Dr. A. Rachel Leheny Ph.D. | Website: | https://www.calcimedica.com | ||||
CALC 3.50 Stock Price CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Stock Details
Positive 0.31
CalciMedica Announces Presentations at Upcoming Medical Meetings
Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in...
prnewswire.com·Wed Nov 20 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow